January 22, 2019 10:52 AM EST

EC expands approval of Amgen's Blincyto; FDA gives uniQure green signal to begin Huntington's study in humans, Cytokinetics feedback on SMA trial

Natalie Grover

Reporter

→ The first therapy to win approval for cancer patients in remission with minimal residual disease in Europe is Amgen‘s $AMGN BiTE immunotherapy, Blincyto. The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EC expands approval of Amgen's Blincyto; FDA gives uniQure green signal to begin Huntington's study in humans, Cytokinetics feedback on SMA trial

Natalie Grover

Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

EC ex­pands ap­proval of Am­gen's Blin­cy­to; FDA gives uniQure green sig­nal to be­gin Hunt­ing­ton's study in hu­mans, Cy­to­ki­net­ics feed­back on SMA tri­al

Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

EC expands approval of Amgen's Blincyto; FDA gives uniQure green signal to begin Huntington's study in humans, Cytokinetics feedback on SMA trial